International guidelines for management of individuals with PALB2 GPV have recently been published,11 and PALB2 carriers in the UK undergo breast screening via the National Health Service (NHS) Very High Risk (VHR) Breast Screening programme.12 While some guidelines have addressed management of OC in individuals with RAD51C, RAD51D or BRIP1 GPV,13 there are no UK guidelines available for the management of all cancer risk in this patient group. The gene discussed is RAD51C; the disease is cancer.